← Back to Company DatabaseVisit Website
PathAI
AI-powered pathology for more accurate cancer diagnosis and drug development.
Series C+Boston, MAFounded 2016
About
PathAI builds AI technology for pathology to improve diagnostic accuracy in oncology and accelerate drug development. Its platform helps pathologists analyze tissue samples and supports pharmaceutical companies in clinical trials with quantitative biomarker analysis. The company partners with leading biopharma companies and diagnostic labs worldwide.
Total Funding
$325MKey Product
AISight pathology AI platformGeography
North AmericaKey Investors
General AtlanticTiger GlobalBristol-Myers Squibb
Focus Areas
DiagnosticsAI / Machine LearningDrug Discovery
Technology
AI / Machine LearningImaging / RadiologyDigital Health / Software
Cancer Types
Pan-cancer
Last updated: Feb 4, 2026